Celltrion Unveils Positive Phase III Results of CT-P47 Biosimilar for Rheumatoid Arthritis at EULAR 2024 Celltrion has revealed encouraging findings from its Phase III study of CT-P47, a biosimilar referencing RoActemra® (tocilizumab), presented at the Annual European Congress of Rheumatology…
Celltrion today presented positive Phase III data for CT-P47, a biosimilar referencing RoActemra® in patients with moderate-to-severe rheumatoid arthritis (RA), at the Annual European Congress of Rheumatology (EULAR) 2024. The trial demonstrated that CT-P47 has equivalent efficacy and comparable safety…
Genentech, part of the Roche Group, announced significant results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) with GemOx (R-GemOx) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma…
Sparrow Pharmaceuticals presented data from an ongoing Phase 2 trial of the HSD-1 inhibitor clofutriben (SPI-62) and prednisolone for polymyalgia rheumatica (PMR) at EULAR 2024 in Vienna, Austria (June 12-15). The data suggest that HSD-1 inhibition can enable effective glucocorticoid…
Enveda Biosciences Secures $55M to Advance AI-Driven Drug Development Enveda Biosciences, known for its pioneering use of AI in drug discovery, has announced a $55 million financing round. This round, which includes investments from new backers like Premji Invest, Lingotto…
Zimbabwe has reached maturity level 3 (ML 3) in the WHO’s classification of regulatory authorities for medicines, marking a significant achievement in healthcare infrastructure. This classification, assessed using WHO’s Global Benchmarking Tool with over 260 indicators, signifies the establishment of…
Today, detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) were announced. The study revealed a median OS of 24.6 months (95% CI, 13.4,…
AstraZeneca’s Farxiga (dapagliflozin) has received approval from the US Food and Drug Administration (FDA) to enhance glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older. This approval follows positive results from the pediatric T2NOW Phase…
Cranbury Pharmaceuticals (Cranbury), a wholly-owned subsidiary of Tris Pharma, has announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for the first generic version of Emflaza® oral suspension (deflazacort). This medication is…
The RNA-biomarker company announced today the appointment of Krista McKerracher as Chairperson of the Board of Directors. McKerracher is a seasoned biopharmaceutical leader with a passion for bringing new medicines to patients with life-threatening diseases. She has nearly three decades…
Sibylla Biotech and The University of Texas MD Anderson Cancer Center have announced a strategic collaboration to discover and develop novel small-molecule cancer therapies called Folding Interfering Degraders (FIDs). These therapies disrupt the proper folding of target proteins, leading to…
AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso has been accepted and granted Priority Review in the US for treating adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If…